Publications PUBLICATIONS Publications and Presentations POSTER | SITC ANNUAL MEETING, NOVEMBER 8-12, 2022 Anti-folate Receptor Alpha (FRα) CoStimulatory Antigen Receptor (CoStAR™) Improves T-cell Function Across Physiologically Relevant Ranges of FRα Expression and T-cell Receptor Affinities POSTER | SITC ANNUAL MEETING, NOVEMBER 8-12, 2022 ITIL-306-201: A Multicenter, First-in-Human Phase 1a/1b Study of ITIL-306, an Engineered Autologous TIL Cell Therapy Product, in Adults With Advanced Solid Tumors MANUSCRIPT | American Journal of Cancer Research, August 30, 2022 Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma POSTER | ASCO ANNUAL MEETING, JUNE 3-7 2022 Antitumor activity of T cells expressing a novel anti-FOLR1 CoStAR in a human xenograft murine solid tumor model and implications for in-human studies PRESENTATION | ASGCT ANNUAL MEETING, MAY 18, 2022 Characterization of the Transcriptomic and T-Cell Receptor (TCR) Clonal Heterogeneity of Tumor-Infiltrating Lymphocyte (TIL) Therapy Infusion Products by Single-Cell Sequencing and Correlative Analyses With Clinical Efficacy in Patients With Advanced Cutaneous Melanoma (ASGCT) Poster | SITC Annual Meeting, Nov. 12-14, 2021 Costimulatory Antigen Receptor (CoStAR): A Novel Platform That Enhances the Activity of Tumor-Infiltrating Lymphocytes (SITC) Poster | SITC Annual Meeting, Nov. 12-14, 2021 DELTA 1: A Global, Multicenter, Phase 2 Study of ITIL-168, an Unrestricted Autologous Tumor-Infiltrating Lymphocyte Cell Therapy, in Adult Patients With Advanced Cutaneous Melanoma (SITC) Poster | SITC Annual Meeting, Nov. 12-14, 2021 Potent T-Cell Costimulation Mediated by a Novel Costimulatory Antigen Receptor (CoStAR) With Dual CD28/CD40 Signaling Domains to Improve Adoptive Cell Therapies (SITC) Poster | ESMO Congress, Sep. 16-21, 2021 Treatment Outcomes With Unselected Autologous Tumor-Infiltrating Lymphocytes in Patients With Checkpoint Inhibition–Refractory Advanced Cutaneous Melanoma (ESMO) Poster | AACR Annual Meeting, April 9-14 2021 Clinical Feasibility and Treatment Outcomes With Unselected Autologous Tumor Infiltrating Lymphocyte Therapy in Patients With Advanced Cutaneous Melanoma (AACR PPT) Poster | AACR Annual Meeting, April 9-14 2021 Clinical Feasibility and Treatment Outcomes With Unselected Autologous Tumor Infiltrating Lymphocyte Therapy in Patients With Advanced Cutaneous Melanoma (AACR ePoster) May 2020 Massively parallel interrogation and mining of natively paired human TCRαβ repertoires December 2019 Efficacy of adoptive therapy with tumor-infiltrating lympohocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis November 2018 In vitro analysis of tumor infiltrating lymphocytes engineered with costimulatory antigen receptors delivering targeted costimulation
POSTER | SITC ANNUAL MEETING, NOVEMBER 8-12, 2022 Anti-folate Receptor Alpha (FRα) CoStimulatory Antigen Receptor (CoStAR™) Improves T-cell Function Across Physiologically Relevant Ranges of FRα Expression and T-cell Receptor Affinities
POSTER | SITC ANNUAL MEETING, NOVEMBER 8-12, 2022 ITIL-306-201: A Multicenter, First-in-Human Phase 1a/1b Study of ITIL-306, an Engineered Autologous TIL Cell Therapy Product, in Adults With Advanced Solid Tumors
MANUSCRIPT | American Journal of Cancer Research, August 30, 2022 Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma
POSTER | ASCO ANNUAL MEETING, JUNE 3-7 2022 Antitumor activity of T cells expressing a novel anti-FOLR1 CoStAR in a human xenograft murine solid tumor model and implications for in-human studies
PRESENTATION | ASGCT ANNUAL MEETING, MAY 18, 2022 Characterization of the Transcriptomic and T-Cell Receptor (TCR) Clonal Heterogeneity of Tumor-Infiltrating Lymphocyte (TIL) Therapy Infusion Products by Single-Cell Sequencing and Correlative Analyses With Clinical Efficacy in Patients With Advanced Cutaneous Melanoma (ASGCT)
Poster | SITC Annual Meeting, Nov. 12-14, 2021 Costimulatory Antigen Receptor (CoStAR): A Novel Platform That Enhances the Activity of Tumor-Infiltrating Lymphocytes (SITC)
Poster | SITC Annual Meeting, Nov. 12-14, 2021 DELTA 1: A Global, Multicenter, Phase 2 Study of ITIL-168, an Unrestricted Autologous Tumor-Infiltrating Lymphocyte Cell Therapy, in Adult Patients With Advanced Cutaneous Melanoma (SITC)
Poster | SITC Annual Meeting, Nov. 12-14, 2021 Potent T-Cell Costimulation Mediated by a Novel Costimulatory Antigen Receptor (CoStAR) With Dual CD28/CD40 Signaling Domains to Improve Adoptive Cell Therapies (SITC)
Poster | ESMO Congress, Sep. 16-21, 2021 Treatment Outcomes With Unselected Autologous Tumor-Infiltrating Lymphocytes in Patients With Checkpoint Inhibition–Refractory Advanced Cutaneous Melanoma (ESMO)
Poster | AACR Annual Meeting, April 9-14 2021 Clinical Feasibility and Treatment Outcomes With Unselected Autologous Tumor Infiltrating Lymphocyte Therapy in Patients With Advanced Cutaneous Melanoma (AACR PPT)
Poster | AACR Annual Meeting, April 9-14 2021 Clinical Feasibility and Treatment Outcomes With Unselected Autologous Tumor Infiltrating Lymphocyte Therapy in Patients With Advanced Cutaneous Melanoma (AACR ePoster)
December 2019 Efficacy of adoptive therapy with tumor-infiltrating lympohocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
November 2018 In vitro analysis of tumor infiltrating lymphocytes engineered with costimulatory antigen receptors delivering targeted costimulation
Instil BioInstil Bio